Can VYNE Therapeutics Inc. (VYNE) Future Potential Be Undermined By Current Price Volatility?
VYNE Therapeutics Inc. (NASDAQ:VYNE) has a beta value of 0.74 and has seen 1.01 million shares traded in the last trading session. The company, currently valued at $191.32M, closed the last trade at $3.64 per share which meant it lost -$0.17 on the day or -4.46% during that session. The VYNE stock price is -262.64% off its 52-week high price of $13.20 and 14.56% above the 52-week low of $3.11. If we look at the companys 10-day average daily trading volume, we find that it stood at 0.85 million shares traded. The 3-month trading volume is 887.00K shares. The consensus among analysts is that VYNE Therapeutics Inc. (VYNE) is a Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 7 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.35. VYNE Therapeutics Inc. (NASDAQ:VYNE) trade information  Sporting -4.46% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Tuesday, 06/15/21 when the VYNE stock price touched $3.64 or saw a rise of 13.33%. Year-to-date, VYNE Therapeutics Inc. shares have moved -42.41%, while the 5-day performance has seen it change -11.44%. Over the past 30 days, the shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) have changed 3.12%. Short interest in the company has seen 3.33 million shares shorted with days to cover at 3.87. Wall Street analysts have a consensus price target for the stock at $15.71, which means that the shares value could jump 76.83% from current levels. The projected low price target is $8.00 while the price target rests at a high of $40.00. In that case, then, we find that the current price level is -998.9% off the targeted high while a plunge would see the stock gain -119.78% from current levels. VYNE Therapeutics Inc. (VYNE) estimates and forecasts  Figures show that VYNE Therapeutics Inc. shares have outperformed across the wider relevant industry. The companys shares have lost -46.47% over the past 6 months, with this year growth rate of 55.22%, compared to 16.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 92.80% and 45.00% for the next quarter. Revenue growth from the last financial year stood is estimated to be 55.90%. 4 analysts offering their estimates for the company have set an average revenue estimate of $6.21 million for the current quarter. 4 have an estimated revenue figure of $9.13 million for the next quarter concluding in Sep 2021. Year-ago sales stood $2.42 million and $3.27 million respectively for this quarter and the next, and analysts expect sales will grow by 156.60% for the current quarter and 179.30% for the next. If we evaluate the companys growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -56.50% over the past 5 years. 5 Stocks Under $10 That Are Poised to Take Off Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck. Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck. Add them to your watchlist before they take off! Get the Top 5 Stocks Now! Sponsored  VYNE Dividends  VYNE Therapeutics Inc. is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the companys debt issue. VYNE Therapeutics Inc. (NASDAQ:VYNE)s Major holders  Insiders own 3.23% of the company shares, while shares held by institutions stand at 46.60% with a share float percentage of 48.15%. Investors are also buoyed by the number of investors in a company, with VYNE Therapeutics Inc. having a total of 144 institutions that hold shares in the company. The top two institutional holders are Perceptive Advisors Llc with over 5.72 million shares worth more than $36.14 million. As of Dec 30, 2020, Perceptive Advisors Llc held 11.13% of shares outstanding. The other major institutional holder is Blackrock Inc., with the holding of over 3.0 million shares as of Dec 30, 2020. The firms total holdings are worth over $18.94 million and represent 5.83% of shares outstanding. Also the top two Mutual Funds that are holding companys shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Dec 30, 2020, the former fund manager holds about 2.22% shares in the company for having 1.14 million shares of worth $7.22 million while later fund manager owns 0.98 million shares of worth $6.72 million as of Mar 30, 2021, which makes it owner of about 1.91% of companys outstanding stock.